about
Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in KoreaManagement of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.MMSA-1 expression pattern in multiple myeloma and its clinical significance.Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Lenalidomide in multiple myeloma-a practice guideline.
@ast
Lenalidomide in multiple myeloma-a practice guideline.
@en
Lenalidomide in multiple myeloma-a practice guideline.
@nl
type
label
Lenalidomide in multiple myeloma-a practice guideline.
@ast
Lenalidomide in multiple myeloma-a practice guideline.
@en
Lenalidomide in multiple myeloma-a practice guideline.
@nl
prefLabel
Lenalidomide in multiple myeloma-a practice guideline.
@ast
Lenalidomide in multiple myeloma-a practice guideline.
@en
Lenalidomide in multiple myeloma-a practice guideline.
@nl
P2093
P2860
P356
P1433
P1476
Lenalidomide in multiple myeloma-a practice guideline.
@en
P2093
P2860
P304
P356
10.3747/CO.20.1252
P577
2013-04-01T00:00:00Z